What Happened?
Shares of genomics company Illumina (NASDAQ: ILMN) jumped 7.7% in the afternoon session after Wall Street analysts lifted their price targets due to an expected improvement in clinical sales and new catalysts, while market participants increasingly viewed the company's gene-sequencing technology as infrastructure for artificial intelligence applications as reported by TipRanks.
Analysts increased their price targets based on projected improvements in clinical sales and potential upcoming catalysts for the business. Gene-sequencing technology determines the genetic sequence of organisms, and investors increasingly consider genomic data generation as foundational infrastructure for artificial intelligence applications. Higher price targets from Wall Street analysts indicate expectations that the stock will trade at higher valuation levels.
The shares closed the day at $293.84, up 7.6% from the previous close.
Is now the time to buy Illumina? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Illumina’s shares are quite volatile and have had 17 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 11 months ago when the stock gained 22.4% on the news that it reported third-quarter 2025 financial results that beat profit expectations and raised its full-year guidance. Illumina announced non-GAAP earnings of $1.34 per share, which was well above analyst estimates of $1.17. While revenue for the quarter remained flat year on year at $1.08 billion, it also surpassed expectations. The positive market reaction was largely fueled by the company's improved forecast.
Management raised its full-year adjusted earnings per share guidance to a midpoint of $4.70, a 4.4% increase from its previous outlook.
Illumina is up 119% since the beginning of the year, and at $293.75 per share, it has set a new 52-week high. Despite the year-to-date gain, investors who bought $1,000 worth of Illumina’s shares 5 years ago would now be looking at only $757.13.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
